Jaguar Health Addresses Nasdaq Publicly Held Shares Deficiency After Delisting Notice
JAGX is trading near its 52-week low of $2.68 (8.2% above the low) on elevated volume (24× avg).
Summary
Jaguar Health received a Nasdaq delisting notice for insufficient publicly held shares but quickly took action by exercising warrants to regain compliance, though the $1.00 bid price issue remains.
Key Events · Corporate Governance and Compliance · JAGX
-
Nasdaq Delisting Notice Received
On May 1, 2026, Nasdaq notified Jaguar Health of non-compliance with the minimum 500,000 publicly held shares requirement, triggered by the 1-for-35 reverse stock split on April 30, 2026.
-
Publicly Held Shares Deficiency Addressed
The company facilitated the exercise of pre-funded warrants on May 4, 2026, increasing publicly held shares to 513,939, and is awaiting Nasdaq's formal confirmation of compliance.
-
Ongoing Bid Price Non-Compliance
Jaguar Health remains non-compliant with Nasdaq's minimum $1.00 bid price requirement, which must be cured after the publicly held shares issue is resolved.
Analysis · JAGX · Life Sciences
This 8-K details Jaguar Health's immediate response to a Nasdaq delisting notice received on May 1, 2026, for failing to meet the minimum 500,000 publicly held shares requirement following its recent 1-for-35 reverse stock split. The company quickly addressed this by facilitating the exercise of pre-funded warrants on May 4, 2026, increasing its publicly held shares to 513,939. While this action appears to cure one delisting threat, the company still needs to regain compliance with Nasdaq's $1.00 minimum bid price rule. This event highlights the company's ongoing struggle to maintain its Nasdaq listing amidst severe financial distress and previous warnings.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $2.68 to $462.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.